Pathology of Hepatitis c Nephropathy

Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03476031
Collaborator
(none)
50
1
13
3.9

Study Details

Study Description

Brief Summary

Hepatitis c associated glomerulonephritis is an immune complex disease that occurs in 21% of patients who have HCV infection.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: renal biopsy

Detailed Description

Hepatitis C virus infection is a major public health problem with an estimated global prevalence of 3% and an estimated 5-20% of infected patients will develop liver cirrhosis .The Prevalence of Hepatitis C infection in end stage renal disease is greater than in the general population especially in those on hemodialysis which reflects nosocomial transmission of the disease in the hemodialysis environment.

Hepatitis C associated glomerulonephritis is an immune complex disease that occurs in 21% of patients who have HCV infection. It most commonly presents as membranoproliferative and mixed cryoglobulinemia It characterized by an indolent course in one third of patients , remission in another third and relapsing course in the remaining patients with potential progression to advanced chronic kidney disease.

mechanism of injury : Chronic Hepatitis C is primarily associated with type II cryoglobulinemia , in which the primary mechanism of injury is vasculitis that occurs via immune complex deposition.

hepatitis C virus related glomerular disease :

Type I membranoproliferative was the most common finding associated with mixed cryoglobulinemia but other forms of glomerulonephritis were associated with Hepatitis c like mesangial glomerulonephritis,focal and segmental glomerulonephritis,minimal change nephropathy,membranous nephropathy , Fibrillary glomerulonephritis,immunotactoid glomerulopathy,IgA nephropathy, vasculitic renal involvement ,poly arteritis nodosa and interstitial nephritis .

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Case-Crossover
Time Perspective:
Cross-Sectional
Official Title:
Different Histopathological Patterns in Patients With HCV Nephropathy
Anticipated Study Start Date :
Nov 1, 2018
Anticipated Primary Completion Date :
Oct 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
study group

patients with hepatitis c nephropathy detected by lab and renal biopsy

Diagnostic Test: renal biopsy
needle biopsy will be taken from the kidney tissue then, diagnosed

Outcome Measures

Primary Outcome Measures

  1. prevalence of histopathological pattern in patients with hepatitis C virus [one year]

    prevalence of histopathological pattern in patients with hepatitis C virus

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • it will be conducted on chronic hepatitis C patients with chronic kidney disease .

  • The participants will be classified according to their estimated GFR by modified MDRD equation and

  • they will be recruited from the renal unit of internal medicine, Assiut University Hospitals and assiut hepatitis viruses unit-ministry of health, Egypt.

Exclusion Criteria:
Patients will be excluded if the underlying causes of CRF are as follows:

chronic pyelonephritis,obstructive uropathy,Polycystic kidney disease,Patients with ESRD on regular hemodialysis,patients with advanced liver cirrhosis,hepatocellular carcinoma,Patients on steroids or immunosuppressive drugs and Solitary kidney.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Assuit University Assuit Egypt 7115115

Sponsors and Collaborators

  • Assiut University

Investigators

  • Study Director: Mohamed Tohammy, PhD, Faculty of medicine , internal medicine ,Assuit university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mahmoud Essmat Mohammad, principal investigator, Assiut University
ClinicalTrials.gov Identifier:
NCT03476031
Other Study ID Numbers:
  • DHPP
First Posted:
Mar 23, 2018
Last Update Posted:
Mar 23, 2018
Last Verified:
Mar 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 23, 2018